Additionally, patient-derived gastric cancer organoids expressing high levels of GLI2 were found to be highly resistant to chemotherapeutic drugs epirubicin, oxaliplatin, and 5-fluorouracil compared to those without GLI2 expression in both in vitro and in vivo, while treatment with GANT61 resensitized the organoids to chemotherapy [103]. Here, GLI2 is linked to gastric cancer.